Ser676

Site Information
LNEkPRLsFADRALI SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 447905

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 , 4 , 6 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 29 ) , mutation of modification site ( 26 , 29 ) , phospho-antibody ( 1 , 27 , 28 , 29 ) , western blotting ( 1 , 29 )
Disease tissue studied:	breast cancer ( 3 , 7 , 28 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 , 3 ) , gastric cancer ( 20 ) , gastric carcinoma ( 20 ) , leukemia ( 22 ) , chronic myelogenous leukemia ( 22 ) , lung cancer ( 7 , 18 ) , non-small cell lung cancer ( 7 , 18 ) , non-small cell lung adenocarcinoma ( 18 ) , ovarian cancer ( 3 ) , fibrosarcoma of soft tissue ( 1 )
Relevant cell line - cell type - tissue:	'muscle, skeletal' ( 12 ) , breast ( 2 , 3 ) , BT-20 (breast cell) ( 7 ) , Calu-1 (squamous) ( 1 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 8 ) , Flp-In T-Rex-293 (epithelial) ( 8 ) , H2077 (pulmonary) ( 7 ) , H322M (pulmonary) ( 7 ) , HCT116 (intestinal) ( 24 ) , HEK293T (epithelial) ( 29 ) , HeLa (cervical) ( 6 ) , HeLa S3 (cervical) ( 25 ) , HeLa_Meta (cervical) ( 21 ) , HeLa_Pro (cervical) ( 21 ) , HeLa_Telo (cervical) ( 21 ) , HT1080 (fibroblast) ( 1 ) , HUES-9 ('stem, embryonic') ( 19 ) , Jurkat (T lymphocyte) ( 4 , 10 , 11 , 13 , 15 , 16 , 17 , 26 , 27 , 29 ) , K562 (erythroid) ( 6 , 22 , 23 ) , MCF-7 (breast cell) ( 28 ) , MDA-MB-468 (breast cell) ( 7 ) , MKN-45 (gastric) ( 20 ) , NCI-H1395 (pulmonary) ( 7 ) , NCI-H157 (pulmonary) ( 7 ) , NCI-H1666 (pulmonary) ( 7 , 18 ) , NCI-H2030 (pulmonary) ( 7 ) , NCI-H520 (squamous) ( 7 ) , ovary ( 3 ) , PC9 (pulmonary) ( 7 )

Upstream Regulation
Treatments:	antibody ( 27 ) , estradiol ( 28 ) , okadaic_acid ( 29 ) , phorbol_ester ( 27 ) , RSL3 ( 1 )

Downstream Regulation
Effects of modification on PKCT:	enzymatic activity, induced ( 26 )
Effects of modification on biological processes:	transcription, altered ( 29 )

References
1	Chen X, et al. (2022) Identification of HPCAL1 as a specific autophagy receptor involved in ferroptosis. Autophagy, 1-21 35403545 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
5	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
6	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
7	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
8	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
9	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
10	Mulhern D (2012) CST Curation Set: 13107; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
11	Mulhern D (2012) CST Curation Set: 13112; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
12	Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876 22673903 Curated Info
13	Mulhern D (2011) CST Curation Set: 13106; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
14	Rikova K (2011) CST Curation Set: 13122; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
15	Mulhern D (2011) CST Curation Set: 12682; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
16	Guo A (2011) CST Curation Set: 12455; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V) Curated Info
17	Guo A (2011) CST Curation Set: 11850; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S/TD/EXD/E) Immunoaffinity Beads Cat#: 1994 Curated Info
18	Rikova K (2011) CST Curation Set: 10901; Year: 2011; Biosample/Treatment: cell line, NCI-H1666/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
19	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
20	Moritz A (2010) CST Curation Set: 9979; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
21	Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81 20097925 Curated Info
22	Rikova K (2010) CST Curation Set: 9327; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
23	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
24	Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64 19369195 Curated Info
25	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info
26	Thuille N, et al. (2005) Critical role of novel Thr-219 autophosphorylation for the cellular function of PKCtheta in T lymphocytes. EMBO J 24, 3869-80 16252004 Curated Info
27	Freeley M, Volkov Y, Kelleher D, Long A (2005) Stimulus-induced phosphorylation of PKC theta at the C-terminal hydrophobic-motif in human T lymphocytes. Biochem Biophys Res Commun 334, 619-30 16009340 Curated Info
28	Castoria G, et al. (2004) Role of atypical protein kinase C in estradiol-triggered G1/S progression of MCF-7 cells. Mol Cell Biol 24, 7643-53 15314172 Curated Info
29	Liu Y, et al. (2002) Phosphorylation of the protein kinase C-theta activation loop and hydrophobic motif regulates its kinase activity, but only activation loop phosphorylation is critical to in vivo nuclear-factor-kappaB induction. Biochem J 361, 255-65 11772397 Curated Info